Laboratory Co. of America Holdings (NYSE:LH) Shares Bought by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC lifted its stake in shares of Laboratory Co. of America Holdings (NYSE:LH) by 275.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,475 shares of the medical research company’s stock after acquiring an additional 35,559 shares during the period. O Shaughnessy Asset Management LLC owned 0.06% of Laboratory Co. of America worth $11,116,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of LH. Graney & King LLC acquired a new position in shares of Laboratory Co. of America in the 4th quarter valued at $26,000. Fortitude Family Office LLC raised its position in shares of Laboratory Co. of America by 312.5% in the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the period. Geneos Wealth Management Inc. boosted its holdings in Laboratory Co. of America by 309.8% in the fourth quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 127 shares during the last quarter. Human Investing LLC purchased a new stake in Laboratory Co. of America during the fourth quarter valued at about $39,000. Finally, True Wealth Design LLC increased its stake in Laboratory Co. of America by 3,660.0% during the third quarter. True Wealth Design LLC now owns 188 shares of the medical research company’s stock worth $42,000 after acquiring an additional 183 shares during the last quarter. 95.94% of the stock is owned by institutional investors and hedge funds.

Laboratory Co. of America Stock Performance

Shares of LH opened at $232.80 on Tuesday. The firm has a market cap of $19.49 billion, a price-to-earnings ratio of 26.39, a PEG ratio of 1.71 and a beta of 1.12. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $244.68 and its two-hundred day moving average is $234.78. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week high of $258.59.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. Analysts forecast that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th were given a $0.72 dividend. The ex-dividend date was Thursday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.24%. Laboratory Co. of America’s payout ratio is 32.65%.

Wall Street Analysts Forecast Growth

LH has been the subject of a number of research reports. Piper Sandler boosted their target price on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Evercore ISI upgraded shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $260.00 to $265.00 in a research note on Tuesday, January 7th. Bank of America raised their target price on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Jefferies Financial Group increased their price target on Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Finally, Barclays reduced their price objective on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a research note on Friday, February 7th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Laboratory Co. of America has a consensus rating of “Moderate Buy” and an average target price of $269.92.

Insider Activity

In other Laboratory Co. of America news, COO Mark S. Schroeder sold 5,339 shares of Laboratory Co. of America stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $249.23, for a total value of $1,330,638.97. Following the completion of the transaction, the chief operating officer now directly owns 4,960 shares in the company, valued at $1,236,180.80. The trade was a 51.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Adam H. Schechter sold 6,121 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total value of $1,497,319.02. Following the sale, the chief executive officer now owns 86,445 shares in the company, valued at $21,146,175.90. The trade was a 6.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,258 shares of company stock worth $3,753,177. 0.85% of the stock is currently owned by insiders.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.